MX2017014586A - Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio. - Google Patents

Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio.

Info

Publication number
MX2017014586A
MX2017014586A MX2017014586A MX2017014586A MX2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A
Authority
MX
Mexico
Prior art keywords
protein
polyethylene glycol
protein solution
methoxy polyethylene
site
Prior art date
Application number
MX2017014586A
Other languages
English (en)
Inventor
S Rosendahl Mary
B Mantripragada Sankaram
Original Assignee
Antriabio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antriabio Inc filed Critical Antriabio Inc
Publication of MX2017014586A publication Critical patent/MX2017014586A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los ejemplos incluyen un método para hacer un conjugado de proteínas PEGiladas. El método puede incluir proporcionar una solución acuosa de proteínas. La solución acuosa de proteínas puede incluir una proteína, un amortiguador de pH, y un agente quelante. El agente quelante puede elegirse del grupo que consta de un ácido aminopolicarboxílico, un ácido hidroxiaminocarboxílico , una glicina N-sustituida, ácido 2-(2-amino-2-oxoctil) aminoetano sulfónico (BES), y deferoxamina (DEF). El método también puede incluir la introducción de un cianoborohidruro de sodio y un metoxipolietilenglicol aldehído a la solución acuosa de proteínas. El cianoborohidruro de sodio en el metoxipolietilenglicol aldehído puede tener una relación molar que se encuentra en el rango de entre 5:1 a alrededor de 1.5:1. El método puede incluir además la reacción del metoxipolietilenglicol aldehído con la proteína para formar el conjugado de proteínas PEGiladas. El amortiguador de pH puede mantener un pH de la solución acuosa de proteínas que se encuentra en el rango de 4.0 a 4.4 durante la reacción.
MX2017014586A 2015-06-04 2016-05-19 Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio. MX2017014586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170933P 2015-06-04 2015-06-04
PCT/US2016/033190 WO2016196017A1 (en) 2015-06-04 2016-05-19 Amine pegylation methods for the preparation of site-specific protein conjugates

Publications (1)

Publication Number Publication Date
MX2017014586A true MX2017014586A (es) 2018-03-09

Family

ID=57442063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014586A MX2017014586A (es) 2015-06-04 2016-05-19 Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio.

Country Status (12)

Country Link
US (1) US10220075B2 (es)
EP (1) EP3302450A4 (es)
JP (1) JP2018516874A (es)
KR (1) KR20180015131A (es)
CN (1) CN107708679A (es)
AU (1) AU2016270302B2 (es)
BR (1) BR112017023145A2 (es)
CA (1) CA2981501A1 (es)
MX (1) MX2017014586A (es)
RU (1) RU2730848C2 (es)
WO (1) WO2016196017A1 (es)
ZA (1) ZA201708573B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115029204A (zh) * 2022-07-15 2022-09-09 曾会明 一种具有sod活性的酒及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
WO2003084985A1 (fr) 2002-04-11 2003-10-16 Mochida Pharmaceutical Co., Ltd. Peptide chimiquement modifie a l'aide de polyethyleneglycol
AU2003273300A1 (en) 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
DE60313786T2 (de) 2002-09-27 2008-01-24 F. Hoffmann-La Roche Ag Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
KR101177340B1 (ko) 2003-01-06 2012-08-30 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
CA2518336A1 (en) 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
CA2521381C (en) * 2003-04-11 2020-05-26 Kenneth Hinds Method for preparation of site-specific protein conjugates
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
WO2005061701A1 (ja) 2003-12-24 2005-07-07 Shionogi & Co., Ltd. タンパク質のポリマー複合体の製造方法
JP2008500275A (ja) 2003-12-31 2008-01-10 セントカー・インコーポレーテツド Ｎ末端の遊離チオールを有する新規な組み換えタンパク質
KR20060029770A (ko) 2004-10-04 2006-04-07 주식회사 펙스피어 Ｇｌｐ－１의 선택적 ｐｅｇ 접합체 및 그 제조방법
DE602006017202D1 (de) 2005-05-13 2010-11-11 Lilly Co Eli Pegylierte glp-1-verbindungen
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
AU2007267798A1 (en) 2006-05-26 2007-12-06 Ipsen Pharma S.A.S. Methods for site-specific pegylation
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
JP2008156283A (ja) * 2006-12-25 2008-07-10 Kyowa Hakko Kogyo Co Ltd 水溶性ポリマー修飾ポリペプチドの製造方法
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
CA2775287A1 (en) 2009-09-25 2011-03-31 Vybion, Inc. Polypeptide modification
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
WO2012054882A1 (en) 2010-10-21 2012-04-26 Kci Licensing, Inc. Debridement hand tool
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
KR101746686B1 (ko) 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체
JP6055817B2 (ja) * 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
CN102786590A (zh) 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
EP3412314A1 (en) 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof

Also Published As

Publication number Publication date
KR20180015131A (ko) 2018-02-12
CA2981501A1 (en) 2016-12-08
RU2017145825A3 (es) 2019-11-18
ZA201708573B (en) 2019-08-28
RU2730848C2 (ru) 2020-08-26
WO2016196017A1 (en) 2016-12-08
EP3302450A1 (en) 2018-04-11
EP3302450A4 (en) 2019-01-16
BR112017023145A2 (pt) 2018-07-10
US20160354478A1 (en) 2016-12-08
AU2016270302B2 (en) 2020-09-17
US10220075B2 (en) 2019-03-05
JP2018516874A (ja) 2018-06-28
AU2016270302A1 (en) 2017-10-19
RU2017145825A (ru) 2019-07-10
CN107708679A (zh) 2018-02-16

Similar Documents

Publication Publication Date Title
HRP20190878T1 (hr) Modificirane aminokiseline koje sadrže azidnu grupu
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
MX2019001253A (es) Conjugados de proteina-agente activo y metodo para su preparacion.
NZ719036A (en) Anti-pdl1 antibody formulations
WO2013038375A3 (en) Methods for making saccharide-protein glycoconjugates
NI201700076A (es) Complejos radiofarmacéuticos
EA201690744A1 (ru) Конъюгаты белок-полимер-лекарственное средство
MY162570A (en) Buffer system for protein purification
NZ703581A (en) Anti-cd70 antibody drug conjugates
MX370679B (es) Polipéptidos de unión hiperglicosilados.
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
BR112015010700A2 (pt) composições dérmicas contendo aminoácidos não naturais higroscópico
MX2012003296A (es) Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina.
MY156211A (en) Method for preparation of an aqueous glyphosate concentrate composition having mixture of amine salts
WO2014207708A3 (en) Amino acid and peptide conjugates and conjugation process
MX2014007125A (es) Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados.
BRPI0807054A8 (pt) Mistura de sais, composição aquosa, e, método de preparação da composição
MX2022005884A (es) Tecnologías de conjugación dirigida.
BR112015023233A2 (pt) conjugados de hemoglobina, composição farmacêutica e métodos de tratamento
MX2017014586A (es) Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio.
WO2017136623A8 (en) Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
AR094987A1 (es) Proceso mejorado para la preparación a alto rendimiento de un complejo polipeptídico fisiológicamente activo
MX2020012350A (es) Anticuerpos anti-cd63, conjugados y usos de estos.
CY1115161T1 (el) Διαδικασια για την παραγωγη 2-[(3,5-διφθορο-3'-μεθοξυ-1,1'-διφαινυλ-4-υλ)αμινο]νικοτινικου οξεος